← Eichor
Study identifier: NCT07140198 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hyperbaric Oxygen Therapy to Improve Autologous Fat Graft Intake in Irradiated Breast

Condition: Breast Reconstruction · Lipofilling · Hyperbaric Oxygen Therapy  ·  Sponsor: University Hospital, Geneva

PhaseNA
Planned participants16
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) enhances fat graft survival in lipofilling procedures in irradiated breast cancer patients. The main questions it aims to answer are: Does it improve fat graft survival ? Evaluate safety and tolerability of HBOT in this setting? Researchers will compare patient receiving HBOT to a control group without HBOT to see if. Sixteen female patients will undergo two autologous fat grafting sessions: one with HBOT and one without, in a randomized sequence. Patients will undergo three MRI during the study to evaluate the fat retention rate.

This description comes directly from the study's public registry record.

Talk to the study team

Dominik André-Lévigne, MD, PhD  ·  +41 (0)22 372 79 97  ·  dlev@hug.ch

Matteo Scampa, MD  ·  +41 (0)79 55 38 542  ·  asmp@hug.ch

Always discuss trial participation with your own doctor first.

Locations (1)

Geneva University HospitalsGeneva, Canton of Geneva, SwitzerlandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07140198